Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals.

[1]  E. Bonora,et al.  [Metabolic syndrome and cardiovascular diseases]. , 2008, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[2]  S. Grundy,et al.  Obesity, metabolic syndrome, and cardiovascular disease. , 2004, The Journal of clinical endocrinology and metabolism.

[3]  A. Nissinen,et al.  The inverse relation of average population blood pressure and stroke mortality rates in the seven countries study: A paradox , 1997, European Journal of Epidemiology.

[4]  Tomás Pantoja,et al.  Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22. , 2003 .

[5]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[6]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[7]  A. Evans,et al.  Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. , 2002, Atherosclerosis.

[8]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[9]  M. Di Napoli,et al.  Inflammation, Hemostatic Markers, and Antithrombotic Agents in Relation to Long-Term Risk of New Cardiovascular Events in First-Ever Ischemic Stroke Patients , 2002, Stroke.

[10]  V. Athyros,et al.  Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[11]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[12]  D. Tanné,et al.  Blood Lipids and First-Ever Ischemic Stroke/Transient Ischemic Attack in the Bezafibrate Infarction Prevention (BIP) Registry: High Triglycerides Constitute an Independent Risk Factor , 2001, Circulation.

[13]  G. Vega.  Obesity, the metabolic syndrome, and cardiovascular disease , 2001 .

[14]  J. Avorn.  Unhealthy ageing: functional and socioeconomic impact. , 2001, European heart journal.

[15]  D. Mikhailidis,et al.  Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? , 2001, Cardiovascular research.

[16]  B. Buckley.  Healthy ageing: ageing safely. , 2001, European heart journal.

[17]  R. D'Agostino,et al.  Elevated midlife blood pressure increases stroke risk in elderly persons: the Framingham Study. , 2001, Archives of internal medicine.

[18]  R. Sacco,et al.  High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. , 2001, JAMA.

[19]  D. Levy,et al.  Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. , 2001, The American journal of cardiology.

[20]  M. Fisher,et al.  Imaging of Acute Stroke , 2001, Cerebrovascular Diseases.

[21]  F. Kronenberg,et al.  Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. , 2001, Atherosclerosis.

[22]  H. Hashimoto,et al.  High serum bilirubin level is inversely associated with the presence of carotid plaque. , 2001, Stroke.

[23]  M. Di Napoli,et al.  Prognostic Influence of Increased C-Reactive Protein and Fibrinogen Levels in Ischemic Stroke , 2001, Stroke.

[24]  D. Mikhailidis,et al.  The Effect of Atorvastatin on Serum Lipids, Lipoprotein(a) and Plasma Fibrinogen Levels in Primary Dyslipidaemia – A Pilot Study Involving Serial Sampling , 2000, Current medical research and opinion.

[25]  E. Chimonas.  The treatment of coronary heart disease: an update. Part 2: Mortality trends and main causes of death in the Greek population. , 2001 .

[26]  P Glasziou,et al.  Pravastatin therapy and the risk of stroke. , 2000, The New England journal of medicine.

[27]  P Bélisle,et al.  Iron stores and coronary artery disease: a clinical application of a method to incorporate measurement error of the exposure in a logistic regression model. , 2000, Journal of clinical epidemiology.

[28]  H. Milionis,et al.  Lipoprotein (a) and stroke , 2000, Journal of clinical pathology.

[29]  Jing Fang,et al.  Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992 , 2000 .

[30]  F. Nieto,et al.  Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? , 2000, Atherosclerosis.

[31]  R. Gillum,et al.  Assessment of serum albumin concentration as a risk factor for stroke and coronary disease in African Americans and whites. , 2000, Journal of the National Medical Association.

[32]  W. Landau,et al.  Is cholesterol a risk factor for stroke?: No. , 1999, Archives of neurology.

[33]  A. Demchuk,et al.  Is cholesterol a risk factor for stroke?: Yes. , 1999, Archives of neurology.

[34]  L. Lemberg,et al.  Stroke risk, cholesterol and statins. , 1999, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[35]  G. Hankey,et al.  Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations* , 1999, The Lancet.

[36]  P. Giral,et al.  Low Free-Thyroxine Levels are a Risk Factor for Subclinical Atherosclerosis in Euthyroid Hyperlipidemic Patients , 1999, Journal of cardiovascular risk.

[37]  B. Longo-Mbenza,et al.  Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans? , 1999, International journal of cardiology.

[38]  A. Folsom,et al.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.

[39]  H. Hobbs,et al.  Lipoprotein(a): intrigues and insights. , 1999, Current opinion in lipidology.

[40]  G. Di Minno,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Barry J. Davis,et al.  Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial , 1998, Annals of Internal Medicine.

[42]  J. Papadakis,et al.  Lipids and stroke: neglect of a useful preventive measure? , 1998, Cardiovascular research.

[43]  N. Taub,et al.  Influence of nutritional status on clinical outcome after acute stroke. , 1998, The American journal of clinical nutrition.

[44]  H Schultz,et al.  Tobacco or health: A global status report. , 1998, Annals of Saudi medicine.

[45]  J. Kjekshus,et al.  Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). , 1998, The American journal of cardiology.

[46]  G. Lippi,et al.  Standardization and Clinical Management of Lipoprotein(a) Measurements , 1998, Clinical chemistry and laboratory medicine.

[47]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[48]  P. Wilson,et al.  Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.

[49]  J. Tuomilehto,et al.  Risk factors for death from stroke in middle-aged Lithuanian men: results from a 20-year prospective study. , 1996, Stroke.

[50]  K. Fung,et al.  Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. , 1996, Biochemical pharmacology.

[51]  J. Webster,et al.  Risk factors for ischaemic heart disease and stroke mortality in young and old hypertensive patients. , 1995, Journal of human hypertension.

[52]  P. Vokonas,et al.  Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. , 1995, American journal of epidemiology.

[53]  G. Boysen,et al.  Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study , 1994, BMJ.

[54]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[55]  M. Bond,et al.  Postprandial Triglyceridemia and Carotid Atherosclerosis in Middle‐Aged Subjects , 1992, Stroke.

[56]  Ruth Bonita,et al.  Epidemiology of stroke , 1992, The Lancet.

[57]  J. Matías‐Guiu,et al.  Ischemic stroke in young adults. II. Analysis of risk factors in the etiological subgroups , 1990, Acta neurologica Scandinavica.

[58]  D. Reed.  The paradox of high risk of stroke in populations with low risk of coronary heart disease. , 1990, American journal of epidemiology.

[59]  M. Mancini,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction. , 1990, Arteriosclerosis.

[60]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[61]  D. Mccarty,et al.  Release of platelet constituents by monosodium urate crystals. , 1977, The Journal of clinical investigation.